Shilpa Medicare Limited (BOM:530549)
India · Delayed Price · Currency is INR | Market Cap | 52.93B |
| Revenue (ttm) | 13.43B |
| Net Income (ttm) | 1.37B |
| Shares Out | 195.58M |
| EPS (ttm) | 7.01 |
| PE Ratio | 38.59 |
| Forward PE | 18.69 |
| Dividend | 0.50 (0.18%) |
| Ex-Dividend Date | Sep 17, 2025 |
| Volume | 5,320 |
| Average Volume | 8,990 |
| Open | 288.75 |
| Previous Close | 289.95 |
| Day's Range | 276.45 - 292.00 |
| 52-Week Range | 265.25 - 501.60 |
| Beta | 0.10 |
| RSI | 17.25 |
| Earnings Date | Feb 9, 2026 |
About Shilpa Medicare
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clo... [Read more]
Financial Performance
In 2024, Shilpa Medicare's revenue was 12.88 billion, an increase of 11.69% compared to the previous year's 11.53 billion. Earnings were 782.93 million, an increase of 145.63%.
Financial StatementsNews
Shilpa Medicare receives Initial Authorization for Rotigotine transdermal patch in European
Shilpa Medicare Limited, headquartered in Raichur, Karnataka, has announced that it has received Initial Authorization from European regulatory authorities recommending...
Shilpa Medicare Ltd (BOM:530549) Q2 2026 Earnings Call Highlights: Record EBITDA and Strategic ...
Shilpa Medicare Ltd (BOM:530549) Q2 2026 Earnings Call Highlights: Record EBITDA and Strategic Growth Initiatives
Q2 2026 Shilpa Medicare Ltd Earnings Call Transcript
Q2 2026 Shilpa Medicare Ltd Earnings Call Transcript
Shilpa Medicare launches world’s first NODUCA Therapy for MAFLD after CDSCO approval
Shilpa Medicare has rolled out a breakthrough treatment for metabolic dysfunction-associated fatty liver disease (MAFLD) with the launch of NODUCA™...
Shilpa Medicare Q2 Results: Net profit jumps 144% YoY to Rs 44 crore, revenue up 7.6%
Shilpa Medicare has announced a strong set of Q2 numbers, showing a sharp improvement in profitability along with steady revenue...
Shilpa Medicare shares jump nearly 3% after positive Phase 3 results for once-weekly Ondansetron injection OERIS™
Shares of Shilpa Medicare Ltd gained nearly 3% on Monday, hitting an intraday high of Rs 385.80 before settling at...
Shilpa Medicare announces positive Phase 3 results for OERIS™ — once-weekly Ondansetron injection for chemotherapy-induced nausea and vomiting
Shilpa Medicare Limited has announced the successful completion of its Phase 3 clinical trial for OERIS™ (Ondansetron Extended-Release Injection), a...
Shilpa Pharma Lifesciences wins EcoVadis Gold Medal for excellence in sustainability
Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited, has been awarded the prestigious Gold Medal by EcoVadis...
Shilpa Medicare sells 31% stake in Sravathi Advance Process Technologies for ₹49.6 crore; brings in new strategic investors
Shilpa Medicare Limited announced that it has entered into a Share Purchase Agreement and Shareholders’ Agreement with Ash Ingredients Inc....
Shilpa Medicare sells 31% stake in Sravathi Advance Process Technologies for Rs 49.6 crore
Shilpa Medicare Limited has announced that it has entered into a Share Purchase Agreement and Shareholders’ Agreement dated October 27,...
Blood donation camp held on birthday
Raichur: KH Honneshaiah, head of operations at Shilpa Medicare, emphasised the importance of blood donation, stating that it has the potential to save.
Shilpa Medicare shares jump over 4% as EMA grants nod for Rivaroxaban Orodispersible Films
Shares of Shilpa Medicare Limited surged 4.22% on Tuesday, September 23, trading at ₹853.00 on the NSE. The company’s market capitalization stood at ₹83.42 billion. The rally came after the pharma com...
Shilpa Medicare jumps another 2.5% as stock extends rally on Saudi JV announcement
Shares of Shilpa Medicare surged another 2.5% in Wednesday’s session, taking their two-day rally to over 5%, after the company announced plans to set up a new joint venture in Saudi Arabia with Pharma...
Shilpa Medicare shares jump 2% after its subsidiary forms JV with Saudi Pharma giant PPI
Shilpa Medicare shares surged over 2% in early morning trade after the pharmaceutical giant announced a major step toward expanding its international presence with a new joint venture in Saudi Arabia....
Shilpa Medicare subsidiary forms strategic JV with Saudi Pharma giant PPI
Shilpa Medicare has taken a significant step toward expanding its global footprint with a new joint venture in Saudi Arabia. The pharmaceutical powerhouse has partnered with Pharmaceutical Industries ...
Shilpa Medicare Q1 Results: Revenue rises 9.9% to Rs 321 crore, Net profit jumps over 3x YoY
Shilpa Medicare Ltd. reported a sharp jump in profitability for the quarter ended June 30, 2025, with consolidated net profit surging to ₹46.89 crore, up over threefold from ₹14.06 crore in the year-a...
Shilpa Medicare shares jump 3% after CDSCO approval for NorUDCA tablets
Shilpa Medicare Limited shares surged by 3% in morning trade following a major announcement from the company. As of 9:18 AM, the shares were trading 3.83% higher at Rs 863.85. The Central Drugs Standa...
Shilpa Medicare gets CDSCO approval for NorUDCA tablets 500 mg, marks first global clearance for NAFLD treatment
Shilpa Medicare Limited has announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO) for its Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg for the treat...
Shilpa Medicare shares jump nearly 5% after USFDA issues EIR with VAI for Bengaluru unit
Shares of Shilpa Medicare Ltd surged nearly 5% on Wednesday, July 16, trading at ₹934.95 on NSE at 10:09 AM — up ₹42.45 from the previous close of ₹892.50 — after the company announced that its Bengal...
Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), has successfully completed a Good Manufacturing Practice (GMP) inspection conducted by ...
Antique cuts target on Shilpa Medicare to Rs 1,090, retains ‘Buy’ on long-term monetization potential
Antique Broking has maintained a Buy rating on Shilpa Medicare (SLPA) while cutting the target price to ₹1,090 from ₹1,525, citing strong revenue growth in Q4FY25 but tempered expectations for the nea...
Top stocks to watch today, May 27: Lupin, Aurobindo Pharma, NHPC, KEC International, Shilpa Medicare and more
Indian benchmark indices ended higher on Monday, May 26, 2025, supported by positive domestic and global cues. The BSE Sensex gained 455.37 points (0.56%) to close at 82,176.45, while the NSE Nifty50 ...
Shilpa Medicare subsidiary partners with Orion Corporation to commercialize Recombinant Human Albumin in Europe
Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biocare Private Limited, has entered into a strategic agreement with Orion Corporation, a pharmaceutical company based in...
Shilpa Medicare shares climb nearly 4% after USFDA EIR for subsidiary, gains European GMP nod for biologics unit
Shares of Shilpa Medicare rose 3.86% to ₹721.75 on the NSE in early trade on Wednesday after the company announced multiple regulatory approvals across its units. The stock opened at ₹701.20 and touch...
Shilpa Medicare’s Bengaluru facility secures GMP approval from EMA for Oral Mouth Dissolving Films and Transdermal Systems
Shilpa Medicare Limited, a leading pharmaceutical company, has announced that its Unit VI facility in Dabaspet, Bengaluru, Karnataka has received Good Manufacturing Practice (GMP) approval from the Eu...